-  Minimum age of 18 Years<br/><br/>          -  Voluntarily agreement to participate in this study<br/><br/>          -  filled in and signed Informed Consent<br/><br/>          -  release of medical records for regulatory or research purposes<br/><br/>          -  clinically organ-confined prostate cancer<br/><br/>          -  recommended and planned robot-assisted radical prostatectomy<br/>
-  Age 18- 42 (upon starting COH);<br/><br/>          -  BMI <30 kg/m2;<br/><br/>          -  <3 prior ART cycles (IVF, ICSI and related procedures);<br/><br/>          -  Baseline (day 2-3 of cycling) FSH <15 IU/L and E2 <80 pg/mL;<br/><br/>          -  Normal uterine cavity as per recent hysterosalpingogram, sonohysterogram or<br/>             hysteroscopic exam (i.e. no polyp or protruding sub-mucosal fibroid);<br/><br/>          -  At least 3 retrieved oocytes;<br/><br/>          -  Patient has given written informed consent.<br/>
DISEASE CHARACTERISTICS:<br/><br/>          -  Diagnosis of primary craniopharyngioma by MRI and CT scan (initial diagnosis)<br/><br/>               -  Patients with only cystic sellar or parasellar malformation (e.g., Rathke pouch<br/>                  cysts or suprasellar cysts) are allowed but will undergo observation only<br/><br/>        PATIENT CHARACTERISTICS:<br/><br/>        Performance status<br/><br/>          -  Not specified<br/><br/>        Life expectancy<br/><br/>          -  Not specified<br/><br/>        Hematopoietic<br/><br/>          -  Not specified<br/><br/>        Hepatic<br/><br/>          -  Not specified<br/><br/>        Renal<br/><br/>          -  Not specified<br/><br/>        PRIOR CONCURRENT THERAPY: Not specified<br/>
all patients independent of the underlying cardiac disease
-  Must be between 18-85 years old<br/><br/>          -  Must have been diagnosed by his/her doctor with overactive bladder at least 6 months<br/>             ago<br/><br/>          -  Must weigh at least 50 kg (110 lbs)<br/><br/>          -  Must be willing and able to record information regarding bladder function into a<br/>             diary (provided)<br/><br/>          -  Must be willing and able to complete the entire course of the study<br/>
-  Patients with a diagnosis of unresectable intermediate stage hepatocellular carcinoma<br/>             (BCLC-B) for whom the decision has been taken by the investigator to prescribe<br/>             Nexavar (the BCLC intermediate stage (BCLC-B) consists of Child-Pugh A and B patients<br/>             with large/multifocal HCC who do not have cancer related symptoms, macrovascular<br/>             invasion or extrahepatic spread).<br/>
-  Women over 18 years with endometriosis-associated pain, like dysmenorrhea,<br/>             dyspareunia, lower abdominal pain, low-back pain, rectal pain, defecation pain (only<br/>             one criterion needs to be fulfilled for study inclusion);<br/><br/>          -  Participants are in good general health except for endometriosis related problems;<br/><br/>          -  Except for endometriosis, no existence of an obvious diseases which could cause<br/>             chronic pain or which could cause abdominal pain;<br/><br/>          -  The participant must have a desire to have children;<br/><br/>          -  Participants must be able to give their consent and must understand the risks<br/>             associated with a participation in the study;<br/><br/>          -  There must be a signed and dated informed consent which was accepted by the local<br/>             ethic committee<br/>
-  Histologically or cytologically proven prostate cancer, locally advanced or<br/>             metastatic, or rising PSA (prostate-specific antigen) after failed local therapy, and<br/>             the patient scheduled to receive androgen deprivation therapy<br/><br/>          -  Serum testosterone levels ≥ 125 ng/dl (1.25 ng/ml, 1.25 microg/l, 4.3 nmol/l)<br/>             measured by any laboratory or on site within the previous 6 months or at study start<br/><br/>          -  Karnofsky performance index > 70<br/><br/>          -  Expected survival ≥ 9 months<br/>
-  Signed written informed consent;<br/><br/>          -  Males or females between 18 and 70 years of age;<br/><br/>          -  Surgically resected squamous cell carcinomas of the hypopharynx, oropharynx, larynx<br/>             and oral cavity with high risk of locoregional recurrence not more than 6-9 weeks<br/>             (maximum) ago;<br/><br/>          -  To be categorized as high risk patients have to fulfil at least one of the following<br/>             criteria:<br/><br/>               -  R0 - resection <5 mm margin<br/><br/>               -  R1 - resection<br/><br/>               -  Extracapsular nodal extension;<br/><br/>          -  no previous chemotherapy, radiotherapy;<br/><br/>          -  Performance status ECOG: 0 - 1;<br/><br/>          -  Contraception in male and female patients if of childbearing potential, willingness<br/>             to use effective contraceptive method for the study duration and 2 months<br/>             post-dosing;<br/><br/>          -  Adequate renal, liver and hematological functions (within maximum 9 weeks until<br/>             surgery):<br/><br/>               -  Adequate bone marrow function: neutrophils > 1.5 x 10^9/L, platelets > 100 x<br/>                  10^9/L, hemoglobin > 10.0 g/dL<br/><br/>               -  Adequate liver function: Bilirubin < 2.0 mg/dL, AST, ALT, AP, γ-GT < 3 x ULN<br/><br/>               -  Adequate renal function: creatinine clearance > =60 ml/min<br/><br/>          -  No distant metastases;<br/>
1. CP CML within 6 months of diagnosis<br/><br/>               -  CP-CML will be defined by (i) <15% blasts in bone marrow; (ii) <30% blasts plus<br/>                  promyelocytes in bone marrow; (iii) <20% basophils in peripheral blood; (iv)<br/>                  ≥100 × 10^9/L platelets (≥100,000/mm^3); (v) No evidence of extramedullary<br/>                  disease except hepatosplenomegaly; AND (vi) No prior diagnosis of AP-CML or<br/>                  BP-CML<br/><br/>          2. Cytogenetic assessment must demonstrate the BCR-ABL fusion by presence of the t(9;22)<br/>             Philadelphia chromosome<br/><br/>               -  (a)Variant translocations are only allowed provided they are assessable for<br/>                  cytogenetic response utilizing conventional cytogenetic techniques; (b)<br/>                  Conventional chromosome banding must be performed; AND (c) A minimum of 20<br/>                  metaphases must be assessable at entry<br/><br/>          3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2<br/><br/>          4. Adequate hepatic function as defined by the following criteria:<br/><br/>             (a) Total serum bilirubin ≤1.5 x upper limit of normal (ULN), unless due to Gilbert's<br/>             syndrome; (b) Alanine aminotransferase (ALT) ≤2.5 × ULN; AND (c) Aspartate<br/>             aminotransferase (AST) ≤2.5 × ULN<br/><br/>          5. Adequate renal function as defined as defined by serum creatinine <1.5 x ULN<br/><br/>          6. Adequate pancreatic function as defined by serum lipase and amylase ≤1.5 × ULN<br/>
Inclusion Criteria:<br/><br/>          -  Diagnosis of Pseudoxanthoma elastcium based on histopathologic and/or genetic testing<br/>
-  Community dwelling men and postmenopausal women who were ambulatory before sustaining<br/>             a low-trauma, unilateral femoral neck fracture (displaced or nondisplaced)<br/><br/>          -  Other than femoral neck fracture, be free of incapacitating conditions and have a<br/>             life expectancy of at least 2 years<br/><br/>          -  Have received or are eligible for treatment with internal fixation (sliding hip screw<br/>             or multiple cancellous screws) for the femoral neck fracture (the surgical procedure<br/>             itself is not performed as part of this study)<br/><br/>          -  Have given written informed consent (participant or proxy) after being informed of<br/>             the risks, medications, and study procedures<br/>
-  Advanced Stage IIIB or IV NSCLC<br/><br/>          -  Eastern Oncology Cooperative Group (ECOG) Performance Status 0 or 1<br/><br/>          -  Prior therapy defined as 1 prior systemic therapy for advanced disease<br/><br/>          -  Documented disease progression during or following most first line therapy for<br/>             advanced disease<br/><br/>          -  Adequate hematologic, hepatic, renal function<br/>
-  Metastatic Castration-Resistant Prostate Cancer Progression after one or two prior<br/>             cytotoxic chemotherapies<br/><br/>          -  At least one chemotherapy must have contained docetaxel<br/><br/>          -  Eastern Cooperative Oncology Group (ECOG) Performance Status <= 2<br/><br/>          -  Medical or surgical castration with testosterone < 50 ng/dL<br/><br/>          -  Adequate bone marrow, hepatic and renal function<br/><br/>          -  Potassium >= 3.5 mmol/L<br/><br/>          -  Able to swallow the study drug whole as a tablet<br/><br/>          -  Informed Consent<br/>
-  Main Inclusion at Screening:<br/><br/>               1. Subject has symptoms of OAB (urinary frequency and urgency with urgency<br/>                  incontinence) for >= 3 months prior to the screening visit<br/><br/>               2. Subject is willing and able to complete the micturition diary and questionnaires<br/>                  correctly, including collection and measurement of urine output for 3 days prior<br/>                  to each visit;<br/><br/>               3. Subject has symptoms of "wet" OAB (urinary frequency and urgency with<br/>                  incontinence or mixed incontinence with predominant urgency incontinence), and<br/>                  reports an average of at least 2 incontinence episodes per day.<br/><br/>          -  Main Inclusion at Run-in (Visit 2):<br/><br/>               1. Subject experiences on average at least 1 episode of urgency (grade 3 or 4) with<br/>                  or without incontinence per 24-hour period during the 3-day micturition diary<br/>                  period.<br/><br/>               2. Subject experiences on average at least 2 incontinence episodes per 24-hour<br/>                  period during the 3-day micturition diary period.<br/><br/>               3. Subject experiences on average at least 8 micturitions (excluding incontinence<br/>                  episodes) per 24-hour period during the 3-day micturition diary period.<br/><br/>          -  Main Inclusion at Randomization (Visit 3):<br/><br/>               1. Subject experiences at least 1 incontinence episode during the 3-day micturition<br/>                  diary period and wishes to increase their treatment for OAB symptoms.<br/>
Inclusion criteria:<br/><br/>          -  Prostate cancer with at least one cancer-related bone lesion with or without hormonal<br/>             treatment.<br/><br/>          -  Breast cancer with at least one cancer-related bone lesion<br/><br/>          -  Negative pregnancy test at screening in case of child-bearing potential and<br/>             Performance status ECOG 0-2<br/><br/>          -  Normal liver and kidney function<br/><br/>          -  Prior surgery, chemotherapy and radiotherapy is allowed. At least 4 weeks must have<br/>             elapsed since the completion of surgery, chemotherapy and radiotherapy to breast or<br/>             bone.<br/><br/>
Inclusion Criteria:<br/><br/>          -  Diagnosis of Pseudoxanthoma elastcium based on histopathologic and/or genetic testing<br/>
-  Male or female subjects ≥ 18 years of age with anemia of chronic kidney disease (CKD)<br/>             at screening<br/><br/>          -  Estimated glomerular filtration rate (eGFR) of < 60 mL/min/1.73 m2 (Modification of<br/>             Diet in Renal Disease or the formula according to Matsuo, et al.)<br/><br/>          -  Not on dialysis and not expected to begin dialysis during the treatment period of the<br/>             study (at least 16 weeks from randomization)<br/><br/>          -  Treated with darbepoetin via intravenous (IV) or subcutaneous (SC) route with a<br/>             weekly, bi-weekly, or monthly dose, having had no more than one dose change within 8<br/>             weeks prior to randomization<br/><br/>          -  At least one kidney<br/><br/>          -  Mean screening hemoglobin (Hb) concentration of 10.0 to 12.0 g/dL<br/><br/>          -  Men who agree to use adequate contraception when sexually active or women without<br/>             childbearing potential<br/>
-  Body mass index between 22 and 40 kg/m²<br/><br/>          -  Subjects meeting pre-defined estimated glomerular filtration rate criteria and<br/>             creatinine clearance rate<br/><br/>               -  Normal  (≥90 mL/min/1.73 m2)<br/><br/>               -  Mild (60-89 mL/min/1.73 m2)<br/><br/>               -  Moderate (45-59 mL/min/1.73 m2)<br/><br/>               -  Moderate (>30-44 mL/min/1.73 m2)<br/>
-  Newly diagnosed patients with de novo or secondary AML<br/><br/>          -  Intermediate or poor risk<br/><br/>          -  In first complete remission<br/><br/>          -  Age 51-70 years<br/><br/>          -  Fit for the procedure<br/><br/>          -  Fit for further consolidation chemotherapy<br/>
-  histologically confirmed head and neck squamous cell carcinoma<br/><br/>          -  tumor is located in a previously irradiated area with at least 50 Gy or there is an<br/>             overlap of radiation fields with resulting total doses greater than 90 Gy to expect<br/><br/>          -  tumor size and localization allow high dose re-irradiation (individual decision)<br/><br/>          -  exclusion of distant metastases<br/><br/>          -  Time interval between pre-irradiation and re- irradiation at least 1 year for local<br/>             recurrence; at least 6 months for secondary tumor disease<br/><br/>          -  age ≥ 18 years<br/><br/>          -  previous radiotherapy treatment plans available<br/><br/>          -  pre-treatment imaging (pre re-irradiation) available<br/><br/>          -  good general condition (ECOG 0-1)<br/><br/>          -  dental treatment performed, if necessary<br/><br/>          -  in case of surgery before re-irradiation: resection status is R-1 or R-2<br/><br/>          -  patient able to understand the intention and procedures of the trial, written<br/>             informed consent<br/>
•Healthy male or female subjects aged 18-55 years of any ethnic origin.<br/>•Body weight between 50 and 100 kg (extremes included).<br/>•Healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram, and clinical laboratory parameters.<br/>•Females of non-childbearing potential, defined as surgically sterile or post-menopausal.<br/>•Males willing to use 2 means of contraceptive methods for at least 3 months after test substance administration.<br/>•Normal lung function (FVC and FEV1 at least 80% of predicted values) at screening.<br/>•Written consent to participate in the study.<br/>
- patients > 18 years of age	<br/>- arterial occlusion in one or both of the lower extremities concurrent with acute ischemia causing decompensation ( Rutherford Stage IIA-III)
-  1. Subjects who signed informed consent.<br/><br/>          -  2. Male subjects ≥18 and ≤79 years of age; female subjects ≥18 and     ≤79 years of<br/>             age of non-childbearing potential<br/><br/>          -  3. Weight within a BMI range of 19.0-35.0 kg/m2.<br/><br/>          -  4. CLCr according to Cockcroft Gault equation of:<br/><br/>               -  50-80 mL/min (mild renal impairment)<br/><br/>               -  30- <50 mL/min (moderate renal impairment)<br/><br/>               -  <30 mL/min (severe renal impairment)<br/><br/>               -  subjects receiving dialysis for ≥3 months before dosing (ESRD)<br/>
-  Female adult patients, >/= 18 years of age<br/><br/>          -  HER2-positive advanced breast cancer (metastatic or locally recurrent, inoperable)<br/>             relapsing after completed adjuvant Herceptin therapy<br/><br/>          -  Indication for first-line treatment with Perjeta in combination with Herceptin and<br/>             chemotherapy according to the Summary of Product Characteristics<br/><br/>          -  Prior Herceptin therapy as systemic adjuvant treatment (postoperative treatment in a<br/>             potentially curable setting); additional upfront neoadjuvant Herceptin therapy is<br/>             allowed<br/><br/>          -  No prior chemotherapy and/or immunotherapy for advanced (metastatic or locally<br/>             recurrent, inoperable) HER2-positive breast cancer<br/>
Female patients for who the treating physician decides that treatment with long acting FSH<br/>        150µg in a GnRH-antagonist protocol is indicated.<br/>
Group 1 (sepsis patients): adult patients who are asked two weeks after the diagnosis of severe sepsis and / or septic shock and written consent to provide a piece of their tonsils<br/>Group 2 (chronic tonsillitis): adult patients with 3 or more episodes of recurrent acute tonsillitis per year that are scheduled for routine tonsillectomy<br/>Group 3 (tonsil hyperplasia): adult patients without acute or chronic tonsillitis in history that are scheduled for routine tonsillectomy due to rhonchopathy or obstructive sleep apnea syndrome<br/>
All patients being diagnosed with Gastrointestinal Stromal Tumors and undergoing systemic target treatment will be included.
Severe aortic stenosis and positive heartteam vote for TAVR<br/>
Admission to the Emergency Department with symptoms consistent with ACS:<br/>- Typical chest pain (with or without ECG-changes, but no ST-elevation) suggestive of unstable angina or non-ST-elevated myocardial infarction (NSTEMI)<br/>- Troponin negative  at admission according to the current clinical practice<br/>Patient willing and able to give written informed consent<br/>
none
Care-dependent people with a dignosed dementia, living in a nursing home
History of arterial hypertension or healthy volunteers
multimorbidity, therapy with oral anticoagulation, minimum of one additional medication over a longer period of time, can give written consent to take  part in the study
- patients with calcifying tendinitis which has proven refractory to conservative treatment and who are treated with shoulder arthroscopy in our clinic<br/>- minimum age 18 years<br/>- no maximum age
1. Histopathologically documented CTCL stage ≥ Ib and grading by EORTC (Appendix K)<br/>Staging, EORTC classification<br/>2. Pretreatment with PUVA if a continuation of the PUVA is no longer possible or with inadequate response<br/>3. Karnofsky performance status> 60%<br/>4. Age ≥ 18 years<br/>5. Adequate organ function (blood count, liver, kidney, cardiac function, electrolytes, lipids)<br/>6. Neg. Pregnancy test, efficient contraception in male and female patients (bexarotene could lead to decreased efficacy of hormonal contraceptives)<br/>7. No other active malignancy<br/>8. No topical chemotherapy, photopheresis or interferon treatment to 28 days prior to study entry<br/>9. No topical treatment (steroids, tar-bath), superficial radiotherapy, treatment with other retinoids or beta-carotene two weeks ago baseline *<br/>10. No serious systemic disease or infection at study entry<br/>11. No participation in another study in the last 14 days prior to study entry<br/>12. No pre-treatment with Targretin<br/>13. Lack of psychological, familial, sociological or geographical obstacles that hinder the study protocol or the follow-up control<br/>14. No contraindications to treatment with bexarotene (known hypersensitivity to retinoids, hypervitaminosis A, status after pancreatitis, alcohol abuse, drugs that can be toxic to the pancreas or increase lipid levels, uncontrolled diabetes mellitus, uncontrolled (thyroid disorder)<br/>15. A signed consent of the patient<br/>*Continuous topical steroid applications before and during treatment withTargretin
The study will include patients who <br/>are receiving a fixed partial denture or telescopic crowns, are at least 18 years old, have given informed consent
Inclusion criteria was a minimum age of 18 years and a written consent after a detailed explanation of the investigation,<br/>Cancer pain
Able to fluently speak and understand German language, existent ostium secundum atrial septal defect (ASD II), presence of a hemodynamically significant ASD II (right ventricular volume overload determined by transthoracic echo (TTE)), defect hole(s) to be covered by an available Ceraflex ASD device, sufficient margin to place the device, Informed Consent prior to treatment and willing to return for the post-treatment evaluation at the implanting institution after 6 month<br/>
Documented HIV-infection, age of at least 18 years, documented triple-class-resistance (NRTIs, NNRTIs, PIs or INSTIs), documented by at least one resistance test), written informed consent
Students attending one of the orthodontic courses of the WWU in the summer semester 2017
Intervention or surgery during hospitalisation
Hospitals with intensive care unit (participants of the trial are hospitals, not patients!)
Patients aged 18 years and older<br/>- - - Diabetes mellitus type 2 (insulin-dependent diabetes mellitus (IDDM) and noninsulin-dependent diabetes mellitus (NIDDM))<br/>- - - Clinical significant diabetic macular edema (diffuse or focal)<br/>- - - Visual acuity (decimal) reduced by diabetic macular edema to ≤ 0,3 and ≥ 0,05 (LogMar ≤ 1,3 and ≥ 0,5) stated by EDTRS charts.<br/>- - - Signed informed consent<br/><br/>
non-elective admitted patients, who are less than 18 years of age at the time of admission
• Male and female patients over 18 years (no upper age limit), who are participating in an alcohol detoxification therapy and taking the dietary-supportive supplement (Eusano formulation)<br/>• Pure alcohol dependence<br/>• No known contraindications<br/>• Written informed consent of the patient to the prospective collection, distribution, analysis of the data and for publication of the results.
Inclusion criteria for patients with myocardial infarction:<br/>first event (STEMI or NSTEMI), percutanous coronary intervention; no valvular defect<br/><br/>Inclusion criteria for patients with stroke:<br/>first stroke ever;<br/>all transient ischemic attacks (not only first events)
-  Has histologically confirmed diagnosis of RCC with clear cell component with or<br/>             without sarcomatoid features.<br/><br/>          -  Has locally advanced/metastatic disease (i.e., Stage IV RCC per American Joint<br/>             Committee on Cancer) or has recurrent disease.<br/><br/>          -  Has measurable disease per RECIST 1.1 as assessed by the investigator/site<br/>             radiologist.<br/><br/>          -  Has received no prior systemic therapy for advanced RCC.<br/><br/>          -  Has provided archival tumor tissue sample or newly obtained core or excisional biopsy<br/>             of a tumor lesion not previously irradiated.<br/><br/>          -  Has Karnofsky performance status (KPS) ≥ 70% as assessed within 10 days prior to<br/>             randomization.<br/><br/>          -  If receiving bone resorptive therapy (including but not limited to bisphosphonate or<br/>             RANK-L inhibitor) must have been on stable doses for 4 weeks prior to randomization.<br/><br/>          -  Demonstrates adequate organ function.<br/><br/>          -  Female participants of childbearing potential must be willing to use an adequate<br/>             method of contraception for the course of the study through 120 days after the last<br/>             dose of study drug.<br/><br/>          -  Male participants of childbearing potential must agree to use an adequate method of<br/>             contraception, starting with the first dose of study drug through 120 days after the<br/>             last dose of study drug.<br/>
- One of these three signs: fever, purulent sputum, typical auscultation findings<br/>- An infiltration in X-ray<br/>- Start of anti-infective therapy with Klacid within 24 hours after admission<br/>- The diagnosis is: community acquired
ARDS (acute)<br/>Consent to  study given<br/>Lung CT scan performed before study recruitment
postmenopausal women under the age of 75 years; mean BMI of 25 kg/m2; non-smoker; study participants who gave written consent
Patients age >18 and < 55 years<br/>Patients suffering from persistent subjective or objective  patellofemoral instability after Patellaluxation <br/>Patients undergoing operative Treatment for patella stabilization<br/><br/>
-  Subjects must provide written informed consent prior to performance of study-specific<br/>             procedures or assessments, and must be willing to comply with treatment and follow<br/>             up.<br/><br/>          -  Age ≥ 18 years.<br/><br/>          -  Histologically confirmed adenocarcinoma of the stomach or the gastroesophageal<br/>             junction with either metastatic or locally advanced disease, incurable by operation.<br/><br/>          -  Eastern Cooperative Oncology Group (ECOG) performance status of < or = 2<br/><br/>          -  At least one unidimensional, measurable tumor parameter (according to RECIST 1.1)<br/><br/>          -  No preceding cytotoxic therapy (neoadjuvant or adjuvant treatment allowed if finished<br/>             > 6 months before inclusion)<br/><br/>          -  Adequate organ system function.<br/><br/>          -  Men and women must perform an adequate contraception.<br/><br/>          -  Female subjects who are lactating should discontinue nursing prior to the first dose<br/>             of study drug and should refrain from nursing throughout the treatment period and for<br/>             14 days following the last dose of study drug.<br/>
German-speaking, age between 18 and 65, member of the rehabilitation team
1. Patients who have given their signed declaration of consent and data<br/>protection declaration<br/>2. Males and females aged ≥ 18 years<br/>3. Patients scheduled for transurethral resection of the bladder of a suspected bladder<br/>cancer based on recent findings in cystoscpy that have to be diagnosed at the respective study site prior to Visit 1<br/>4. Patients including multiple baldder tumours or suspicious lesions<br/>5. Patients with initial and/or recurrent bladder cancer<br/>6. Patients with adequate renal and hepatic function according to the<br/>investigator<br/>7. No known anaesthetic risks (risk of narcosis ASA 1-3)<br/>8. All women of child-bearing potential must have a negative serum or<br/>urine pregnancy test at screening and must use hormonal contraception<br/>or intrauterine device (IUD) during the treatment and for at least one<br/>month thereafter.
every Patient with age below 12 years requiring general anesthesia
Multiple Sclerosis patients starting therapy with alemtuzumab<br/>
- First ever stroke within last 3 months<br/>- Stroke patients who are not able to walk alone<br/>
Healthy individuals
Postlingual onset of profound sensorineural hearing loss , no congenital hearing loss ; Hearing loss in opposite ear least PTA ≥ 50 dB<br/>• Freedom or CI500 series implant (Cochlear)<br/>• use the speech processor CP910 with a minimum of 6 months experience <br/>• speech understanding in quiet ( Freiburger words at 70 dB SPL ) in the implanted ear of at least 50 % and understanding in Oldenburg sentence test in quiet at 70 dB at least 80%<br/>• Preferably unilateral CI patients ; in bilateral CI patients fitting should be bilateral.<br/>• language skills : German mother tongue
Moderate to severe stroke (NIHSS>7 and <26)<br/><br/>Ineligibility for iv tPA and no prior iv tPA therapy<br/><br/>Premorbid mRS 0-1<br/><br/>Life expectancy > 6 Months<br/><br/>Treatment can be accomplished within 8 hours after stroke onset<br/>Informed consent by the patient, legal guardian, or independent physician<br/><br/>Imaging criteria:<br/>Occlusion of the M1 segment of the middle cerebral artery (MCA), and/or the intracranial segment of the distal internal carotid artery (ICA), determined by MRA or CTA<br/>CT and CBV map on CTP or DWI with an ASPECT score of 7-10
lung healthy
All patients 18 years or older with a first histological diagnosis of a supratentorial DLGG (WHO°II) from either a stereotactic biopsy or a neurosurgical resection between 2004 and 2012 in the Department of Neurosurgery or the Department of Stereotactic and Functional Neurosurgery of the University Medical Center Freiburg.
Degree of dementia: CDR memory value <2 or MMSE> 9; subjective cognitive impairment, MCI, mild to moderate Alzheimer's disease (ICD<br/>10, NINCDS/ ADRDA criteria)
•Age > 18 and < 90 years of age  with symptoms of myocardial ischemia and angina or angina equivalent (chest pain, abnormal stress testing, abnormal noninvasive testing)<br/>•Patients witch semi recent ( >3 days) acute coronary syndromes can be included but only for the non-culprit vessels and outside of primary intervention during acute myocardial infarction.<br/>•Willing to participate and able to understand, read and sign the informed consent document before the planned procedure<br/>•Eligible for coronary angiography and/or percutaneous coronary intervention<br/>•Coronary artery disease with at least 1 or more visually assessed de novo coronary stenosis (30-90% diameter stenosis) in native major epicardial vessel or its branches by coronary angiogram.<br/>
Skin Tumor in need of excision and skin transplantation
chronic critically ill;<br/>ICUAW (MRC<48); diagnoses of CIP,CIM or both; RASS -1, 1, 0, 1; patiet can perform all tests, allowed to sit in bed, mechanic ventilation, confirmed interesst of patient or guardian
Patients with metastasized renal cell carcinoma treated at the Department of Urology<br/>        (University of Munich - Grosshadern Campus)<br/><br/>        1) with either - Sunitinib (Sutent®), Pazopanib (Votrient ®) bzw. Sorafenib (Nexavar®) as<br/>        first-line therapy<br/><br/>        2.) with Sunitinib (Sutent®), Pazopanib (Votrient ®) bzw. Sorafenib (Nexavar®) as<br/>        second-line therapy after failed first-line therapy, who are off therapy for at least 2<br/>        weeks<br/><br/>        and who have given informed consent to participate in the study<br/>
self-reported weakness of the legs
staff of an institution for disabled persons that consults our psychosomatic consultation in the workplace that we established with this institution
-  Patients who have had pretreatment with single or tandem high dose melphalan therapy<br/>             and autologous stem cell transplantation as first line therapy<br/><br/>          -  at least stable disease after stem cell transplantation<br/><br/>          -  adequate hematological, hepatic and renal lab parameters<br/><br/>          -  karnofsky status of 70 or more<br/>
Diagnosis of social phobia according to the DSM-IV as primary diagnosis as well as a sum score > 30 in the Liebowith social anxiety scale (LSAS)
25 -> 50 year-old persons of both genders, with and without family history of CRC, who gave their written consent to participate in the project
-  Men who agree to use adequate contraception when sexually active or women without<br/>             childbearing potential<br/><br/>          -  Male or female subjects ≥ 18 years of age with anemia of chronic kidney disease (CKD)<br/>             at screening<br/><br/>          -  Estimated glomerular filtration rate of < 60 mL/min/1.73 m2 (Modification of Diet in<br/>             Renal Disease [MDRD] or the formula according to Matsuo, et al)<br/><br/>          -  Not on dialysis and not expected to begin dialysis during the treatment period of the<br/>             study (at least 16 weeks from randomization)<br/><br/>          -  Not treated with any erythropoiesis-stimulating agent (ESA) within 8 weeks before<br/>             randomization<br/><br/>          -  Mean screening Hb concentration < 10.0 g/dL<br/><br/>          -  Body weight of 45 kg to 125 kg, inclusive, at screening<br/>
-  Female subjects 18 years of age or older with FIGO Stages III-IV epithelial ovarian,<br/>             primary peritoneal or fallopian tube cancer with an indication for first-line<br/>             treatment with paclitaxel and carboplatin x 6 cycles (Subjects with pseudomyxoma,<br/>             mesothelioma, adenocarcinoma with an unknown primary tumour, carcinosarcoma, sarcoma,<br/>             mucinous or neuroendocrine histology are excluded<br/><br/>          -  Subjects with FIGO Stage IIIA or IIIB disease must have undergone PDS for ovarian,<br/>             primary peritoneal or fallopian tube cancer within 12 weeks prior to randomization<br/><br/>          -  Subjects with FIGO Stage IIIC or IV disease must either:<br/><br/>          -  Undergo PDS for epithelial ovarian, primary peritoneal or fallopian tube cancer<br/>             within 12 weeks prior to randomization or<br/><br/>          -  Plan to have IDS following 3 cycles of paclitaxel and carboplatin plus AMG 386 or AMG<br/>             386 placebo for biopsy proven epithelial ovarian, primary peritoneal or fallopian<br/>             tube cancer<br/><br/>          -  ECOG performance status of 0 or 1<br/><br/>          -  Adequate bone marrow, renal and hepatic function<br/>
Key inclusion criteria at Screening:<br/>1. ≥ 18 years of age at the time Informed Consent is signed.<br/>2. Diffuse cutaneous SSc (skin thickening on upper arms, upper legs, or trunk).<br/>3. Disease duration ≤ 6 years from the first non-Raynaud’s symptom.  If disease duration is > 3<br/>years and ≤ 6 years, then mRSS ≥ 15.<br/>